European Phased Adaptive Approach

Target entity: European Phased Adaptive Approach
Context triple: [Aegis Ashore (Romania), partOf, European Phased Adaptive Approach]

• A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• B. ICH E8 General Considerations for Clinical Trials
  ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
• C. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• D. APHINITY trial
  The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
• E. Clinical Practices of the University of Pennsylvania
  Clinical Practices of the University of Pennsylvania is the faculty practice plan and outpatient clinical arm of Penn Medicine, providing patient care across a wide range of specialties in collaboration with the University of Pennsylvania’s health system.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: European Phased Adaptive Approach
Target entity description: The European Phased Adaptive Approach is a U.S.-led NATO missile defense strategy for Europe that deploys increasingly advanced land- and sea-based interceptors and radars in successive phases to protect against ballistic missile threats.

• A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• B. ICH E8 General Considerations for Clinical Trials
  ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
• C. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• D. APHINITY trial
  The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
• E. Clinical Practices of the University of Pennsylvania
  Clinical Practices of the University of Pennsylvania is the faculty practice plan and outpatient clinical arm of Penn Medicine, providing patient care across a wide range of specialties in collaboration with the University of Pennsylvania’s health system.
• F. None of above. chosen